Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25670635 | 0.84 | CYP3A4 (0.37) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20813842 | 0.82 | CYP1A2 (0.42) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL25671290 | 0.79 | CYP3A4 (0.39) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24067418 | 0.78 | NOTUM (0.35) | HSD17B10ALDH1A1KDM4EHPGDCYP19A1 | |
| SCHEMBL24067504 | 0.78 | MAOA (0.35) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12775446 | 0.73 | PDE1B (0.51) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24067423 | 0.72 | KDM4E (0.40) | HSD17B10CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL31502050 | 0.70 | ENPP1 (0.67) | — | |
| SCHEMBL24015442 | 0.70 | ENPP1 (0.67) | — | |
| SCHEMBL25670576 | 0.70 | HTR1A (0.46) | HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | HSD17B10 3715/4885CYP1A2 4507/4885CYP3A4 4454/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | HSD17B10 3715/4885CYP1A2 4507/4885CYP3A4 4454/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | HSD17B10 3317/4885CYP1A2 4654/4885CYP3A4 4354/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | HSD17B10 3715/4885CYP1A2 4507/4885CYP3A4 4454/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | HSD17B10 3715/4885CYP1A2 4507/4885CYP3A4 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.